The complexity of providing adequate care after radiation exposure has drawn increasing attention. While most therapeutic development has focused on improving survival at lethal radiation doses, acute hematopoietic syndrome (AHS) occurs at substantially lower exposures. Thus, it is likely that a large proportion of such a radiation-exposed population will manifest AHS of variable degree and that the medical and socioeconomic costs of AHS will accrue. Here, we examined the potential of rBPI 21 (opebacan), used without supportive care, to accelerate hematopoietic recovery after radiation where expected survival was substantial (42%-75%) at 30 days. rBPI 21 administration was associated with accelerated recovery of hematopoietic precursors and normal marrow cellularity, with increases in megakaryocyte numbers particularly marked. This translated into attaining normal trilineage peripheral blood counts 2-3 weeks earlier than controls. Elevations of hematopoietic growth factors observed in plasma and the marrow microenvironment suggest the mechanism is likely multifactorial and not confined to known endotoxin-neutralizing and cytokine downmodulating activities of rBPI 21 . These observations deserve further exploration in radiation models and other settings where inadequate hematopoiesis is a prominent feature. These experiments also model the potential of therapeutics to limit the allocation of scarce resources after catastrophic exposures as an endpoint independent of lethality mitigation.
| I N T R O D U C T I O N
Perhaps more than Hiroshima, the accidents at Chernobyl and Three Mile Island, natural disaster at Fukushima, and omnipresent threat of nuclear detonation highlight that unexpected radiation exposure is a reality that could affect considerable numbers of individuals. As the scope of the resource and managerial challenges after such an event has been increasingly well-delineated, we understand that radiation mitigation strategies must meet an array of efficacy, toxicity, and implementation criteria to be of general value. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] A number of promising strategies that emphasize improving survival of very severely affected individuals have recently emerged, often demanding the use of extensive personnel and other resource intensive medical management. 12 and rev. in 13, 14 A wide range of partial or total body irradiation (TBI) doses can induce profound hematopoietic suppression without causing lethal damage to other organs. It is therefore unsurprising that most proposed radiation mitigation strategies, including hematopoietic cell transplantation, improve some aspect of radiation-induced acute hematopoietic syndrome (AHS). Indeed, in 2015, filgrastim (recombinant human granulocyte colony stimulating factor, rhG-CSF) and pegfilgrastim (PEGylated rhG-CSF), hematopoietic growth factors used to improve recovery from myelosuppressive cancer therapy including transplantation, became the first agents approved for the indication of improving survival in patients exposed to TBI doses associated with hematopoietic suppression. 13 Even lower TBI doses associated with AHS commonly cause some transient damage to gastrointestinal mucosa. [15] [16] [17] As a result, bacteria (including Gram-negative bacteria bearing endotoxin, also known as lipopolysaccharide or LPS, in their plasma membrane) leak into the systemic circulation. [15] [16] [17] [18] [19] In humans, who are particularly endotoxinsensitive, and in animal model systems, both bacterial sepsis and endotoxemia have marked effects on bone marrow (BM) and peripheral blood (PB) cells, and endotoxin itself can induce myelosuppression and hematopoietic stem cell (HSC) exhaustion. [20] [21] [22] Endotoxin sensitivity is interaction both precludes endotoxin from binding to TLR4, its proinflammatory, pro-apoptotic receptor, and potentiates endotoxin clearance. As BPI is abundant in the cytoplasmic granules of polymorphonuclear neutrophils (PMN) and monocytes, [23] [24] [25] [26] TBI-induced hematopoietic suppression results in loss of BPI and its endotoxin neutralization capacity.
Opebacan (rBPI 21 , a 21kD recombinant N-terminal fragment of human BPI) has many advantages as a potential ameliorator of hematopoietic damage caused by radiation. It can be administered subcutaneously (SC), has a long shelf-life and an excellent safety profile in approximately 1200 people of all ages in Phase I-III trials of sepsis and one myeloablative chemoradiotherapy study. 27 -32 rBPI 21 has considerable anti-infective properties 25, 26, 29, 32, 33 and synergizes with antibiotics against multiply-resistant bacteria, 34 potentially of value in radiation disaster settings where concomitant trauma contributes to morbidity and mortality. 35, 36 We previously explored the potential of rBPI 21 to mitigate radiation-induced lethality in a murine model. 37 Thirty-day (D30) mortality after 7 Gy TBI was 95%, and neither SC rBPI 21 nor oral (PO) enrofloxacin (ENR, a fluoroquinolone, used to model suggested supportive care postradiation catastrophe) alone was sufficient to improve survival. However, combinatorial rBPI 21 and ENR treatment, starting 24 hours after TBI, improved D30 survival from 5% to 65%-90% and markedly mitigated AHS.
At the time of our prior study, there was no known role for rBPI 21 in hematopoietic regulation or radiation mitigation, and rBPI 21 and ENR co-administration limited our ability to understand their individual contributions to hematopoietic recovery. Fluoroquinolones had demonstrated some radiation protection but inadequate mitigation in murine models. 38, 39 Moreover, FDA warnings about fluoroquinolone toxicities 40 and the recent association with gastrointestinal perforation 41 have been concerning. We therefore became interested in studying the role of single-agent rBPI 21 in ameliorating AHS and exploring the hypothesis that rBPI 21 ). We estimated that 50% of the cavity was fluid volume, yielding an estimated volume of 3.3 lL/femur. This estimate was used to correct for the dilution of the BM supernatant protein levels. Reported BM supernatant data were calculated using these assumptions. 
| BM cell flow cytometry analysis

| Statistical analysis
Mantel-Cox log-rank was used to compare survival curves (GraphPad Prism 6). PB parameters and BM cell counts were analyzed using an unpaired parametric t-test with Welch's correction (GraphPad Prism 6).
For CBC values, outliers were removed prior to analysis using a modified Z-score (Excel); equal variance was not assumed. For HSC analyses, we fit separate regression models for the log transformed LSK and LK data. We fit linear models in day, as well as models that treated day as a repeated measure. We included interaction terms to enable us to consider differences between TBI alone and VEH and between TBI doses. We selected our final models for the LSK and LK analyses using the Bayesian Information Criterion. We confirmed approximate normality of the residuals from the models through histogram plots and Where appropriate, n sizes are shown in the figure legends. Where indicated in figures, * P < .05, ** P < .01, *** P < .001, **** P < .0001.
| RE SUL TS
3.1 | 6.25 Gy and 6.5 Gy produce a range of intermediate survivals after single fraction TBI
In our studies examining effects of rBPI 21 and ENR co-administration on radiation lethality, a single 7 Gy fraction of TBI produced rapid and profound hematologic suppression and resulted in 95% lethality by D30 in 12 week-old male BALB/c mice. 37 To explore whether rBPI 21 as a single therapeutic could ameliorate severe AHS in a model of single fraction TBI where survival was possible but not universal, we examined the lethality of TBI at 4 different TBI doses: 6 Gy, 6.25 Gy, 6.5 Gy and 7 Gy. Survival determined by Mantel-Cox log rank was significantly different across the 4 dose groups examined (P < .0001, Supporting Information Figure S1 ). D30 survival of the 6.25 Gy cohorts ranged from 60%-75% (mean 68%, total n 5 19 from 2 independent experiments). D30 survival of the 6.5 Gy cohorts ranged from 42%-58% (mean 50%, total n 5 24 from 2 independent experiments). As the survival at these doses was both in the desired intermediate range and sufficient to permit comparisons between untreated and treated cohorts, subsequent experiments to examine hematopoietic effects were performed at both 6.25 and 6.5 Gy.
3.2 | rBPI 21 accelerated trilineage PB count recovery after AHS 3.2.1 | White blood cell (WBC) and PMN recovery Both 6.25 and 6.5 Gy TBI were associated with sustained PB pancytopenia, including >15 days of leukopenia and neutropenia in irradiated controls ( Figure  F1  1 ). In contrast, by D15 after 6.25 Gy, rBPI 21 -treated mice had a trend to more (2-to 3-fold) WBC and PMN than either control ( Figure 1A ,B). After 6.5 Gy ( Figure 1E,F) , that difference was significant for WBC (rBPI 21 vs TBI alone P 5 .01 or VEH P 5 .009) and PMN (rBPI 21 vs TBI alone P 5 .009 or VEH P 5 .01). While median WBC and PMN counts remained low and virtually unchanged through D19 in both irradiated controls, rBPI 21 treatment was associated with higher counts after 6.25 Gy (WBC: rBPI 21 vs TBI alone or VEH P 5 .0003; PMN: rBPI 21 vs TBI alone or VEH P 5 .0001) and 6.5 Gy (WBC: rBPI 21 vs TBI alone P 5 .004 or VEH P 5 .003; PMN: rBPI 21 vs TBI alone or VEH P 5 .002). Only rBPI 21 -treated mice had D19 median WBC (6.25 Gy) and PMN (both doses) above the lower limit of normal (LLN). Similar recovery was not observed in irradiated controls until D30, when virtually all groups had median values above the LLN. rBPI 21 -treated mice also experienced accelerated monocyte recovery (Supporting Information Figure S2 ).
| Platelet recovery
PLT counts recovered with a similar trajectory ( Figure 1C,G) . By D15, rBPI 21 -treated mice had greater median PLT than irradiated controls (6.25 Gy, P 5 .005 vs either irradiated control; 6.5 Gy, P 5 .04 vs either FIG URE 1 rBPI 21 accelerated PB trilineage recovery following TBI. PB and reticulocyte counts were determined on the indicated days after 6.25 Gy (A-D) or 6.5 Gy (E-H). Each box spans the interquartile range, the median is the horizontal bar inside the box and the whiskers show the range from highest to lowest value in n 5 3-9 mice per time point per condition (data aggregated from 2-3 independent experiments). The range of values in unirradiated mice is indicated by the grey shaded area (A-C, E-G). Horizontal bars (D,H) indicate the reticulocyte range in unirradiated mice (3.5-4.2%). * P < .05; ** P < .01; *** P < .001; **** P < .0001 21 -treated mice continued to recover PLT counts rapidly, by 3-fold (6.25 Gy) and 5-fold (6.5 Gy), nearing or exceeding the LLN. During this period, counts in irradiated controls rose < 2-fold, remaining well below the LLN. The median D19
PLT count of rBPI 21 -treated mice was significantly greater than TBI alone or VEH counts (P < .0001 for each) at both TBI doses. By D30, virtually all groups had median counts at or exceeding the LLN.
| Red cell recovery
Median hematocrit (HCT) universally lay below the LLN by D15 (Supporting Information Figure S2 ). VEH and rBPI 21 -treated groups had lower D15 HCT than TBI alone after 6.5 Gy (VEH vs TBI alone P 5 .0006 and rBPI 21 vs TBI alone P 5 .004) but not 6.25 Gy, raising the possibility that injection related bleeding may have contributed to falls in HCT in the more compromised 6.5 Gy mice. Bleeding at rBPI 21 or VEH injection sites (total 28 injections over 14 days) was observed either immediately or as SC hemorrhage at necropsy and was more frequently noted after 6.5 Gy. At D19, HCT had fallen further in irradiated controls, but had risen in rBPI 21 -treated mice, producing significant differences (6.25 Gy: rBPI 21 vs TBI and vs VEH P < .0001; 6.5 Gy: rBPI 21 vs TBI P 5 .0001 and rBPI 21 vs VEH P 5 .0015). By D30, all groups had median HCT above or nearing the LLN. Changes in hemoglobin (Hgb) and red blood cell count (RBC) were similar (Supporting Information Figure S2 ). There was a trend to elevated reticulocyte frequency in rBPI 21 -treated mice by D15 ( Figure 1D,H On D3, BM cell counts/hindlimb were profoundly reduced ( Figure  F2 2A, D). There was a trend to greater ablation at 6. (Figure 2A,D) . In contrast, counts remained 5% of the LLN between D3-19 in irradiated controls, regardless of TBI dose. While all D30 group medians fell above the LLN, rBPI 21 -treated group values exceeded the normal median whereas irradiated controls remained 33%-53% below.
We also compared counts between irradiated treatment groups (Figure 2A,D) . After 6.25 Gy, counts were greater in the rBPI 21 Gy) or neared the LLN (6.5 Gy, Figure 2B ,E). By D30 all rBPI 21 -treated mice in both TBI dose groups had LK counts within the normal range.
In contrast, D3-15 fold-increases were much lower (range, none to 26-fold) in irradiated controls. By D19, median values in both irradiated control groups at both TBI doses remained at 4%-13% of the LLN.
Capacity for delayed recovery of LK in irradiated controls was evident in the 10-to 30-fold increases observed from D19-30. By Day 30, the majority of irradiated control mice had LK counts in the normal range.
LSK recovery was comparable. In rBPI 21 -treated mice, median LSK counts increased by 4.6-fold (6.25 Gy) and 3.3-fold (6.5 Gy) between D3-15 and the majority (6.25 Gy) or some (6.5 Gy) had LSK counts that exceeded the LLN of by D19 ( Figure 2C,F) . By D30, the fraction above the LLN had increased for both TBI doses. In contrast, median LSK counts remained unchanged between D3-15 in both irradiated controls regardless of TBI dose, and at D19 their LSK counts were still only 6%-18% of the LLN.
Despite greater fold increases (ranging 3-to 13-fold) from D19-30, less than 50% of the irradiated controls had LSK counts that neared or exceeded the LLN at D30 after 6.25 Gy and virtually none did so after 6.5 Gy.
We also compared irradiated treatment groups to one another (Table  T1  1 ). For all modelling approaches, we found nonsignificant interactions representing differences between TBI alone and VEH and therefore we combined these two groups into a single category referred to as irradiated controls for the subsequent analyses. The linear model for LK estimated a significantly higher slope for rBPI 21 versus irradiated controls (difference in slopes of 0.036, SE 5 0.006, P < .0001). The linear model for LSK also obtained a significantly higher slope for rBPI 21 than irradiated controls (difference in slopes of 0.024, SE 5 0.005, P < .0001). The selected model for LK retained the interactions between day and rBPI 21 vs irradiated controls and no terms involving dose. The selected model for LSK retained the interactions between day and rBPI 21 vs irradiated controls as well as the interactions between day and dose. The repeated measures models for both LSK and LK obtained significantly higher values for rBPI 21 versus irradiated control results (after Bonferroni correction) for D10, 15 and 19. This is also true at D30, though is not significant at the corrected p-value (Table 1) . Global P-values (5 degrees of freedom) for each analysis for the comparison between rBPI 21 and irradiated controls are both < 0.0001.
| rBPI 21 accelerated recovery of in situ BM cellularity and megakaryocyte counts
The loss of BM hematopoietic elements at D3 was profound ( Figure   2A ,D) at both TBI doses, which precluded meaningful histologic comparisons. Thereafter, rBPI 21 -associated recovery of BM cellularity was more complete than either irradiated control at each time point and TBI dose ( Figure  F3 3A-D). In contrast, we observed no change in the cellularity of either irradiated control through D19 regardless of TBI dose, and D30 median cellularity remained 50% of normal. These histopathologic results were consistent with the BM cell counts shown in . LK and LSK were enumerated by surface phenotype using flow cytometry on indicated days after 6.25 Gy (B,C) or 6.5 Gy (E,F). Data aggregated from 2 to 3 independent experiments per TBI dose, n 5 3-9 animals per time point per condition. Due to the limited number of BM cells after TBI on D3, samples were pooled within treatment groups immediately prior to flow cytometry. * P < .05; ** P < .01; *** P < .001 Gy, and D19-30 at 6.5 Gy ( Figure 3A -C,E).
| rBPI 21 was associated with increased cytokine and hematopoietic growth factor levels
The rapid hematopoietic recovery in rBPI 21 -treated mice led us to examine early levels (D3) of hematopoietic and inflammatory mediators that could have contributed to these later outcomes. For the majority of mediators assessed, D3 plasma levels in rBPI 21 -treated mice were significantly elevated in comparison to both unirradiated and irradiated controls ( Figure  F4 4A-H). In some cases, these effects were only observed at 6.5 Gy or in more singular patterns (Supporting Information Figure   S3 ).
We observed fewer effects in BM supernatant, although the highvolume flush required for sample collection introduced substantial dilution of the extracellular fluid from the cavity which may have impacted assay sensitivity. As described in Methods, we corrected for this dilution to provide some reasonable comparability of concentrations of mediators in the dilute supernatants with that in undiluted plasma. Significant rBPI 21 -associated elevation of G-CSF, KC, and CCL-2 were observed on D3 ( Figure 4I-K) . For KC and CCL-2, median BM supernatant levels were higher than in plasma whereas G-CSF levels were comparable.
Because thrombopoietin (TPO) participates in regulating both HSC and megakaryocyte production, 42, 43 we determined D3 TPO levels in plasma and BM supernatant (Supporting Information Table S1 ). Levels
were not different between the TBI alone and VEH-treated cohorts (at 6.25 Gy P 5 .24, at 6.5 Gy P 5 .94), thus they were combined as irradiated controls for TPO analyses. In comparison to unirradiated controls, plasma levels in irradiated controls rose by 1.6-(6.25 Gy) to 1.5-(6.5
Gy) fold while BM supernatant levels rose 4.5-fold (6.25 Gy) and 9.8-fold (6.5 Gy). The addition of rBPI 21 treatment led to further increases in both plasma and supernatant levels, which were significant in most cases.
3.6 | rBPI 21 improved survival of mice irradiated at 6.5 Gy
Although these studies were designed primarily to examine effects of rBPI 21 on AHS, a limited number of small survival cohorts were also followed. At 6.25 Gy, rBPI 21 did not improve D30 survival (rBPI 21 vs TBI P 5 .2 and rBPI 21 vs VEH, P 5 .93) However, at 6.5 Gy, which was associated with greater D30 mortality, rBPI 21 
| D IS C U S S I O N
The numerous, interactive challenges to providing adequate medical care following substantial radiation exposure are well-delineated in manuscripts describing the intensive resource and operational requirements of responding to a catastrophic event. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Optimal management of individuals with unintended radiation exposure will likely depend upon factors including exposure (dose, type of radiation and body surface involved), extent and type of concomitant trauma, and facilities and resources available for triage and treatment. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 35 As AHS occurs at relatively lower radiation doses than other acute radiation toxicities 10, [44] [45] [46] it is likely that many individuals within a radiation exposed population will manifest hematologic injury of variable degree and duration. Most candidate, and the approved (Neupogen and Neulasta), radiation mitigators improve post-TBI hematopoietic recovery as well as survival although the effects are not equal for all hematopoietic lineages. 13, 14, 47, 48 To obtain FDA designation as a radiation mitigator, the path to approval specifies studies demonstrating a survival advantage in lethal/near-lethal TBI model systems. However, the larger number of individuals will experience more variable partial or TBI exposures less likely to lead to death but highly likely to result in clinically relevant AHS. 1, 10, 45, 49 Streamlined approaches that improve the likelihood and rapidity of trilineage hematopoietic recovery in such populations will decrease the frequency of pancytopenia-related complications and reduce demand on scare resources.
In this report, at TBI doses where D30 survival was 42%-75% . 50 In addition, in a small phase I/II study we conducted in patients receiving myeloablative chemoradiotherapy conditioning for allogeneic hematopoietic cell transplantation, a 72-hour rBPI 21 infusion was well-tolerated and associated with considerably more rapid PLT Data aggregated from 2 to 5 independent experiments at each TBI dose, n 5 3-9 per group. SE 5 standard error.
recovery and substantially fewer infections and Grade 3-5 toxicities in the first 35 days post-transplant than that observed in protocol-eligible cotemporaneous controls. 51 In aggregate, these data support the hypothesis that rBPI 21 could impact transfusion requirements, pancytopenia-related complications including infections, and associated material, personnel and hospitalization utilization postirradiation.
Hematopoietic cell transplant patients become endotoxemic and BPI deficient after chemoradiotherapy-based myeloablation. 37 Moreover, endotoxin ligation of TLR4 and downstream signaling play major roles in aberrant myeloid differentiation, HSC exhaustion and death during sepsis or experimental endotoxemia. 21, 22, [52] [53] [54] Together, these observations first led us to investigate a potential role for rBPI 21 -mediated endotoxin neutralization in AHS mitigation. As rBPI 21 effects had been attributed almost solely to its ability to neutralize endotoxin and ameliorate inflammatory cytokine release during endotoxemia, [23] [24] [25] [26] 30, 31, 34 we anticipated that rBPI 21 administration would be associated with decreased HSC death or damage and decreased levels of inflammatory or hematopoietic mediators that had previously been described as elevated after radiation or during sepsis-related emergency hematopoiesis. 22, [55] [56] [57] [58] Instead, rBPI 21 administration markedly augmented levels of these 21 may produce this effect at least in part by an endotoxin-independent mechanism. In retinopathy models, rBPI 21 was found to act directly on retinal epithelial, pericyte and endothelial cells, 59, 60 influencing growth and apoptotic regulation and inhibition of VEGFinduced angiogenesis. In an organ-on-a-chip model of AHS, an N-terminal FIG URE 4 rBPI 21 augmented early (D3) mediator levels in the plasma and BM supernatant of irradiated mice. Mediator levels in the plasma (A-H) and BM supernatant (I-K) of unirradiated and irradiated treated mice were measured using a bead-based multiplex assay. Samples with undetectable analytes were assigned a value at half the lower limit of detection (variable to each protein/cytokine and specified by the manufacturer). Each box spans the interquartile range, the median is the horizontal bar inside the box and the whiskers show the range from highest to lowest value, n 5 3-11 mice per condition. Levels of IL-1b, IL-2, IL-4, IL-5, IL-10, IL-15, IL-17, and CCL5 levels under all conditions were either unchanged or undetectable in plasma in all groups. Levels of GM-CSF, IFN-y, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1a, MIP-1b, MIP-2, CCL5, TNF-a levels under all conditions were either unchanged or undetectable in BMS in all groups. over a bar indicates a statistical difference between the treatment group and unirradiated mice. # over a bracket indicates a statistical difference between irradiated treatment groups. , # P < .05; , ## P < .01; , ### P < .001; , #### P < .0001 rBPI construct used to perfuse sterile BM stroma and HSC substantially increased hematopoietic cell proliferation. 50 These observations support the notion that endotoxin-independent, direct interactions with cells, potentially including endothelium and pericytes in the hematopoietic microenvironment, led to some of the rBPI 21 effects observed.
Independent of mechanism, elevation of hematopoietic regulators has been previously reported in association with AHS mitigators. Notably, the survival benefit associated with CBLB502 (flagellin)-mediated TBI mitigation was correlated with elevation of plasma G-CSF and IL-6 levels. 55 As blocking either molecule decreased the efficacy of CBLB502, the authors suggested this combination might be a biomarker of an effective AHS mitigation treatment. Furthermore, coadministration of IL-6 and G-CSF has been shown to provide more effective AHS mitigation than either alone. 61 In rBPI 21 -treated mice, levels of these two mediators were 50-100-fold greater than in VEHtreated mice. Moreover, some mediators that rose in association with rBPI 21 administration, including G-CSF, TPO, and IL-6, have been evaluated as possible AHS mitigators in multiple species where they have accelerated single-or multi-lineage recovery. [12] [13] [14] 47, 48, 58, 62, 63 Other mediators that rose in association with rBPI 21 treatment are also known to affect hematopoietic cells. For example, the myeloid growth factor GM-CSF is included as a radiation countermeasure in the Strategic National Stockpile. 13 IL-9 can potentiate megakaryocytopoiesis in conjunction with other mediators, including TPO, 64 and has a critical role in resolving inflammation. 65 CCL2 can reduce HSC cycling, potentially supporting a longer period for repair after TBI and increased HSC survival. 66 Thus, it is possible that the quantitative and temporal relationship of mediators observed in response to rBPI 21 treatment, in conjunction with amelioration of endotoxin-related toxicity, support both hematopoietic recovery and survival through a variety of independent and interactive mechanisms.
Comparisons between therapeutics are always colored by differences in model selection and experimental design and regimens. With these considerable caveats, the effects of rBPI 21 on the time to onset, rate and completeness of hematopoietic recovery after AHS reported here exceed or equal those observed with other agents, including rhG-CSF administration for a similar duration in murine models of sub-lethal TBI. 61 Most reports detail greatest effects on PMN recovery, while effects of equivalent magnitude on erythropoiesis and/or thrombopoiesis are less commonly reported. 13, 14 While PMN are essential to decreasing infectious risk and maintaining tissue integrity, PLT also play a critical role in wound repair and vascular integrity. PLT reconstitution is also an important endpoint as collection of platelets for transfusion is costly, time intensive, yields a product with limited shelf-life, and administration is associated with high risk of reactions and infection. 67 However, the goal of the experiments reported here was not to establish the relative merits of rBPI 21 , but rather to determine the capacity of rBPI 21 to rapidly resolve TBI-induced pancytopenia when given as a single agent in the absence of supportive care. This study suggests that there are likely multiple mechanisms, some novel, that contribute to the effects on hematopoiesis observed here and that these deserve further exploration in regard to normal hematopoietic regulation and other stress conditions such as myelosuppressive therapy, sepsis and acquired or congenital marrow failure. Finally, this report emphasizes the need to identify meaningful endpoints other than improved survival to foster development of approaches that limit the allocation of scarce resources to the large number of individuals expected to experience consequential, but not necessarily irreversible, syndromes such as AHS.
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